Clinical trials have shown that higher expression levels of PD-L1 on tumor cells correlate with improved therapeutic outcomes (14, 15), and the expression of PD-L1 also determines whether ICIs are recommended as a first-line treatment option (16). Here, CD274 is linked to neoplasm.